July 12, 2018
At Mylan, we are committed to delivering better health for a better world. This includes a passion to continue fighting HIV/AIDS. For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable antiretroviral medicines, known as ARVs, in 100 countries around the world. In fact, more than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world’s HIV+ children – depend on a Mylan product.
This year, Mylan is proud to be a major sponsor of International AIDS 2018, the largest health care conference in the world. The event will be held in the Netherlands later this month with the theme of “Breaking Barriers, Building Bridges.” Mylan will host a symposium at the conference titled, “Frontiers in Generic and Low-Cost ARVs in High-, Middle-, and Low- Income Countries: Four Provocative Questions.”
Mylan has a long history of breaking barriers in the treatment of HIV/AIDS. In 2009, Mylan introduced the first generic one-tablet-once-a-day combination for developing countries – only three years after the originator product launched in the U.S. Since that time, Mylan has been the first to market with nearly half of the new products tentatively approved by the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief program, known as PEPFAR.
Mylan was also the first generic drug maker to develop for low- and middle-income countries a heat-stable version of a drug critical for second-line regimens, and is the leading worldwide supplier of pediatric ARVs, including taste-masked and dispersible formulations.
Mylan has long been a supporter of the HIV/AIDS patient community through the sponsorship of free community testing and clinical research. Learn more about Mylan's work with infectious disease here. Watch this video to learn more about Mylan's commitment to people living with HIV/AIDS.